PER-066-01已完成未知
OLANZAPINE VERSUS ZIPRASIDONE IN THE TREATMENT OF SCHIZOPHRENIA
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Men or women between 18 and 75 years of age.
- •Women with reproductive potential should be using a medically accepted method of contraception.
- •Individuals who are reliable, who have a sufficient level of understanding to perform all the tests and exams required by the protocol, who can understand the nature of the study and who have given their informed consent.
- •Patients must meet the diagnostic criteria for schizophrenia (295.10, 295.20, 295.30, 295.90) according to the definition of the Manual of Statistics and Diagnosis of Mental Disorders, Fourth Edition (DSM-IV).
- •At Visit 1, patients must have an initial score greater than or equal to 42 (on a scale of -7) on the BPRS Scale drawn from the PANSS Scale, including a score of 4 or higher on one of the positive items of the PANSS Scale. Patients must also have a minimum score of 4 on the CGI-S Scale.
排除标准
- •Researchers, staff of the center directly affiliated with this study and their direct families. The direct family is defined as the spouse, father, son or brother, whether biological or legally adopted.
- •Congenital long QT syndrome, or QTc interval of> 500 mSeg in Visits 1 or 2 or any of the following abnormalities on the ECG (which is known to confuse the QT interval measurement) that occur in Visits 1 or 2: PR> 250 msec, AV block in 2nd or Ser grade, Defect in intraventricular conduction with QRS duration> 120 msec, Left Branch Block, Blockage, Right Branch, Left Ventricular Hypertrophy, Wolff Parkinson White Syndrome
- •Clinically significant abnormal laboratory results in the randomization when performing the pre-selection (screening) in Visit 1 that could be an impediment for the patient to continue in the study. Patients with prolonged uncorrected hypokalemia (<3.4 meq / 1) or hypomagnesemia (• Treatment with any medication during the last 30 days that has not received regulatory approval at the time of entering the study.
- •Participation in a clinical trial with another medication, including olanzapine, within a period of 1 month (30 days) before entering the study (Visit 1).
- •Treatment with an injectable depot neuroleptic within the period of 1 treatment cycle prior to Visit 1.
- •Treatment with clozapine within 7 days of enrolling in the study.
- •Individuals who have used olanzapine or ziprasidone within 6 months of the start of the trial, and whose treatment has been interrupted due to clinically significant and / or intolerable adverse effects, or who have exhibited a lack of efficacy / response to treatment.
- •A prolactin level of> 200 mg / mL in Visit 1 (300 mg / mL for those patients who are receiving risperidone before Visit 1).
- •Individuals who have completed or who have previously withdrawn from this study.
- •Pregnant or lactating women.
- •Serious, unstable diseases, in which the patient is expected to die within a period of one year, or it is anticipated that the patient will require hospitalization in the intensive care unit within a period of 6 months. These include liver disease (specifically, any degree of jaundice), kidney disease, gastroenterology, respiratory disease, cardiovascular disease (including ischemic heart disease), endocrinology, neurology, immunology, or hematology (specifically, current agranulocytosis with an absolute neutrophil count of <500 mm3)
- •History of narrow-angle glaucoma.
- •History of allergic reaction to the medication (s) of the study.
- •Substance dependency (with the exception of nicotine and caffeine) according to the DSM-IV within the last month.
- •Remoxipride treatment within 6 months (180 days) prior to Visit 2.
- •Any other medication that primarily acts on the central nervous system that is not specified in Section 3.8.
- •History of cardiac arrhythmia, decompensated heart failure, sinus node syndrome, or other disorders in which a decrease in cardiac output or peripheral vascular resistance may place the patient in a situation of medical risk, including acute myocardial infarction, unstable angina pectoris and marked hypotension or ECG abnormalities considered clinically significant by the researcher or the appropriate representative designated by the researcher that could have clinical implications regarding the patient´s participation in the present study.
研究者
相似试验
已完成
不适用
OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF ACUTE MANIAPER-038-99ELI LILLY INTERAMERICA INC.,
进行中（未招募）
不适用
Influence of treatment of olanzapine and ziprasidone on transcapillary glucose transport in human skeletal muscle - Olanzapine or ziprasidone on transcapillary glucose transportHealthy volunteersEUCTR2004-002147-27-ATDepartment of General Psychiatry30
进行中（未招募）
不适用
ZOOM STUDY ZIPRASIDONE AND OLANZAPINE S OUTCOMES IN MANIA A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE ZELDOX 63194;, GEODON 63194; VS OLANZAPINE ZYPREXA 63194; IN THE TREATMENT AND MAINTENANCE OF RESPONSE IN PATIENTS WITH ACUTE MANIA - ZOOM STUDY ZIPRASIDONE AND OLANZAPINE S OUTCOMES IN MANIAAcute maniaMedDRA version: 6.1Level: PTClassification code 10004939EUCTR2005-004391-21-ITPFIZER352
尚未招募
3 期
A comparative study of Olanzapine and Haloperidol in treating Delirium in ICU settingsCTRI/2023/03/051110Pacific Medical College and Hospital
尚未招募
3 期
Olanzapine in pediatric chemotherapy induced nausea and vomiting iIRCT20120415009475N14Vice Chancellor for research of Shahid Beheshti University of Medical Sciences56